Semaglutide cuts BMI by 17.4% in children with obesity in Novo Nordisk’s landmark trial
By: IPP Bureau
Last updated : November 17, 2026 5:12 pm
The trial evaluated once-weekly investigational semaglutide injections at doses of 1.7 mg or 2.4 mg
Novo Nordisk has reported promising results from its Phase 3 STEP Young trial, showing that once-weekly semaglutide injections significantly reduced body mass index (BMI) in children aged 6 to under 12 years living with obesity.
The findings point to the potential of semaglutide as a treatment option for younger children with obesity, a group with limited medical treatment options.
The trial evaluated once-weekly investigational semaglutide injections at doses of 1.7 mg or 2.4 mg, depending on baseline body weight, alongside a reduced-calorie diet and increased physical activity.
The results were striking. At week 68, children receiving semaglutide recorded an estimated mean BMI reduction of 17.4%, compared with a 2.2% increase among those receiving placebo. This represented an estimated treatment difference of 19.7 percentage points under the efficacy estimand.
Under the treatment regimen estimand, BMI fell by 13.5% in the semaglutide group, compared with a 2.7% increase in the placebo group, translating into a treatment difference of 16.2 percentage points.
Perhaps more significantly, 40.4% of children receiving semaglutide were no longer classified as having obesity after 68 weeks, compared with none in the placebo group under the efficacy estimand. More than 85% of participants had class II or class III severe obesity at the beginning of the study.
Both groups received lifestyle interventions, including dietary changes and increased physical activity, throughout the trial.
The findings could have important implications for children living with severe obesity, which is associated with a range of serious health complications, including type 2 diabetes, dyslipidemia, hypertension and obstructive sleep apnea.
Childhood obesity can also take a significant toll on emotional well-being and quality of life. A modelling analysis has suggested that young children with severe obesity whose condition persists could face a reduction in life expectancy of close to 50%.
“Severe obesity can profoundly affect a child’s physical health, emotional well-being, and daily life. This chronic disease also increases the risk of many obesity-related complications that can emerge early and persist into adulthood,” said Ania M. Jastreboff, Professor of Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology) at Yale School of Medicine and Director of the Yale Obesity Research Center (Y-Weight).
“Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child’s trajectory back towards one of improving weight related health.”
Novo Nordisk said semaglutide's overall safety and tolerability profile in STEP Young was consistent with findings from its previous paediatric and adult trials. No unexpected safety concerns were identified, and the trial also found no safety concerns relating to growth or pubertal development.
However, important safety warnings remain. Semaglutide injection 2.4 mg carries a Boxed Warning regarding the potential risk of thyroid tumours, including cancer. It should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects include nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue, dizziness, bloating, belching, gas, heartburn and hair loss, among others.
The findings have also renewed calls for comprehensive, stigma-free obesity care for children and their families.
“Children and families affected by the disease of obesity deserve access to compassionate, evidence-based care that recognizes obesity as a complex, chronic disease,” said Joe Nadglowski, President and Chief Executive Officer of the Obesity Action Coalition (OAC).
Martin Holst Lange, executive vice president, R&D and Chief Scientific Officer (CSO) at Novo, said the findings build on the company's work in paediatric obesity medicine.
"Obesity can have lifelong consequences when it begins in childhood, yet many children and adolescents still lack access to comprehensive care – from prevention and lifestyle modifications to medical treatment where clinically appropriate and approved,” said Martin Holst Lange, executive vice president, R&D and Chief Scientific Officer (CSO) at Novo.
“Building on our pioneering work in pediatric obesity medicine, the STEP Young results highlight the potential of semaglutide, alongside lifestyle modifications, in improving obesity care for children who need medical treatment to achieve better health."
Despite the encouraging findings, semaglutide remains investigational for children under 12 in the United States.
Novo Nordisk clarified that investigational semaglutide injection is not approved for this age group. Its safety and efficacy have not been established, and there is no guarantee that the medicine will become commercially available for the uses currently being studied.
The STEP Young results nevertheless add to growing evidence on the potential role of medical interventions in addressing severe childhood obesity, alongside lifestyle modifications and comprehensive clinical care.